Cognition Therapeutics (CGTX) Receivables - Other (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Receivables - Other data on file, last reported at $3.7 million in Q1 2026.

• Quarterly Receivables - Other fell 23.46% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (down 23.46% YoY) and the FY2025 annual result came in at $9.9 million, up 269.43% from the prior year.
• Receivables - Other slipped to $3.7 million in Q1 2026 per CGTX's latest filing, from $9.9 million in the prior quarter.
• Across five years, Receivables - Other topped out at $9.9 million in Q4 2025 and bottomed at $861000.0 in Q1 2024.
• The 5-year median for Receivables - Other is $2.8 million (2022), against an average of $3.3 million.
• The widest annual swing landed in 2022, when Receivables - Other jumped 742.0%; it then plunged 65.11% in 2023.
• Tracing CGTX's Receivables - Other over 5 years: stood at $3.7 million in 2022, then sank by 65.11% to $1.3 million in 2023, then jumped by 109.68% to $2.7 million in 2024, then soared by 269.43% to $9.9 million in 2025, then sank by 63.15% to $3.7 million in 2026.
• Per Business Quant, the three latest CGTX Receivables - Other figures stand at $3.7 million (Q1 2026), $9.9 million (Q4 2025), and $1.9 million (Q3 2025).

Peer Comparison